+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Changes in pulmonary function and cross-sectional area of trachea and bronchi in asthmatics following inhalation of procaterol hydrochloride and ipratropium bromide



Changes in pulmonary function and cross-sectional area of trachea and bronchi in asthmatics following inhalation of procaterol hydrochloride and ipratropium bromide



American Journal of Respiratory and Critical Care Medicine 149(1): 81-85



To determine the sites of action of inhaled adrenergic and anticholinergic bronchodilators, we used the acoustic reflection technique to measure airway area before and after administration of beta 2-selective adrenoreceptor agonist (procaterol hydrochloride) and quaternary anticholinergic agent (ipratropium bromide). Eight stable individuals with asthma (five men and three women; mean age, 34 +/- 12.7 yr) were studied on 2 days in single-blind randomized crossover fashion when they self-administered (using metered-dose inhaler) two puffs of either procaterol hydrochloride hemihydrate (10 micrograms/puff) or ipratropium bromide (20 micrograms/puff). Maximal expiratory flow-volume curve, specific airway resistance, and cross-sectional areas of three airway segments (extrathoracic tracheal, intrathoracic tracheal, and bronchial) were recorded at baseline and 15, 30, 60, and 120 min after drug administration. Both agents produced significant improvements in FEV1, FVC and forced expiratory flow at 50% of vital capacity (V50), and specific airway resistance (SRaw) as early as 15 min after drug administration. These effects were sustained for the 120 min monitoring period. However, all improvements were significantly greater for procaterol than for ipratropium. By contrast, there was no significant difference between drugs in the increased production in the cross-sectional areas of the three airway segments although there was a nonsignificant trend toward greater increases in tracheal area produced by the anticholinergic agent.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 008285061

Download citation: RISBibTeXText

PMID: 8111604

DOI: 10.1164/ajrccm.149.1.8111604


Related references

Clinical study on benefit and safety of frequent inhalation of aerosolized procaterol hydrochloride in aged acute asthmatics. Nihon Kyobu Shikkan Gakkai Zasshi 30(12): 2105-2111, 1992

Ipratropium bromide in controlled clinical trials. Short communication (II): Time-response measurements of pulmonary function after ipratropium bromide and isoprenaline. Arzneimittel-Forschung 26(5a): 1015-1017, 1976

Ipratropium Bromide, an Anticholinergic Bronchodilator/Behavior of airways resistance in patients with reversible respiratory obstruction following inhalation of various doses of ipratropium bromide. Arzneimittel-Forschung 26(5a): 1017-1020, 1976

Pulmonary effects of sulfur dioxide exposure and ipratropium bromide pretreatment on intrinsic asthmatics. Journal of Allergy & Clinical Immunology 81(1): 316, 1988

Inhalation of high-doses of ipratropium bromide (Atrovent) does not cause any changes in systemic or pulmonary hemodynamics. Casopis Lekaru Ceskych 139(2): 49-50, 2000

Effects of formoterol and ipratropium bromide on repeated cadmium inhalation-induced pulmonary inflammation and emphysema in rats. European Journal of Pharmacology 647(1-3): 178-187, 2011

Ipratropium bromide atrovent as inhalation powder a double blind study of comparison with ipratropium as a pressure aerosol in patients with reversible airway obstruction. Allergy (Copenhagen) 41(1): 37-42, 1986

One-Year Evaluation of the Safety and Efficacy of Ipratropium Bromide HFA and CFC Inhalation Aerosols in Patients with Chronic Obstructive Pulmonary Disease. Clinical Drug Investigation 23(3): 181-191, 2003

Methacholine induced bronchial response after administration of fenoterol procaterol and ipratropium bromide in asthmatic patients. Clinical & Experimental Allergy 20(SUPPL 1): 75, 1990

Pharmacodynamic study of procaterol hydrochloride dry powder inhaler: evaluation of pharmacodynamic equivalence between procaterol hydrochloride dry powder inhaler and procaterol hydrochloride metered-dose inhaler in asthma patients in a randomized, double-dummy, double-blind crossover manner. Methods and Findings in Experimental and Clinical Pharmacology 27(6): 385-389, 2005

Therapy with nebulized beta2 agonists (procaterol) in asthmatic children: pulmonary function and plasma levels after inhalation. Arerugi 56(11): 1372-1377, 2007

Evaluation of cumulative doses of sch 1000 ipratropium bromide in asthmatics. Postgraduate Medical Journal Supplement 51(7): 100, 1975

Prevention of fog-induced bronchospasm by high doses of ipratropium bromide in asthmatics. Respiration; International Review of Thoracic Diseases 50 Suppl 2: 209-211, 1986

Variability in the site of airway responses to ipratropium bromide in chronic asthmatics. Australian & New Zealand Journal of Medicine 12(6): 696, 1982

Factors contributing to broncho dilatation induced by ipratropium bromide in asthmatics. Australian & New Zealand Journal of Medicine 12(6): 686, 1982